Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Participants are randomly allocated to one of two treatment groups. In one group,
participants are given capsules of simvastatin to take orally (by mouth) for 24 months. In
the other group, participants are given placebo (dummy) capsules to take orally for 24
months. At the start of the study, when they receive their medication, participants complete
a number of questionnaires and motor (movement) tests (a walking test and a finger tapping
test). Participants in both groups also attend a further 6 clinic visits after 1, 6, 12, 18
and 24 and 26 months, where they are asked about their health and any medication they are
taking, as well as repeating the questionnaires and motor tests. For 4 of the clinic visits,
the participants will be asked to attend in the 'OFF medication' state (having omitted their
usual PD medication) so that the researchers can get a true picture of their disease without
it being masked by their normal medication.
Phase:
Phase 2
Details
Lead Sponsor:
Plymouth Hospitals NHS Trust University Hospital Plymouth NHS Trust